Archive

Missed a briefing? Here you can find all our past issues.

Here's what we know about Biohub's world model for proteins

May 28, 2026

•

7 min read

Here's what we know about Biohub's world model for proteins

Plus: AI makes prime editing less fragile, Claude gets biosecurity-tested, and Insilico creates a longevity model.

Peter Ottsjö

Retro raises at $1.8B to move aging biology into the clinic

May 24, 2026

•

4 min read

Retro raises at $1.8B to move aging biology into the clinic

Plus: Incyte feeds Genesis its data, and AI designs RNA pseudoknots - without an AlphaFold moment.

Peter Ottsjö

Now it’s undeniable: AI scientists are here

May 21, 2026

•

9 min read

Now it’s undeniable: AI scientists are here

Plus: MouseMapper’s AI maps disease across the whole body, Hugging Face opens a faster DNA model, and Genentech gives virtual cells a tougher test.

Peter Ottsjö

“No virtual cell model actually uses AlphaFold”

May 16, 2026

•

9 min read

“No virtual cell model actually uses AlphaFold”

Plus: Morgan Levine on the wrong AI for aging, AI agents tie humans at protein design, and Isomorphic raises $2.1B.

Peter Ottsjö

May 11, 2026

•

5 min read

Making sense of Isomorphic’s $2B raise

Plus: Young AI talent shuns pharma, DeepMind’s AlphaEvolve reaches genomics, and Kanvas maps the microbiome.

Peter Ottsjö

May 7, 2026

•

7 min read

Physical AI is coming for the wet lab

Plus: ARPA-H’s AI research engine, digital twins for donor lungs, and OpenBind’s new drug-design dataset

Peter Ottsjö

May 4, 2026

•

6 min read

DeepMind says the AI will see you now

Plus: a world model that simulates drug and lifestyle interventions person by person, perturbation prediction clears the bar, and a physics lab trains one model on DNA, RNA, and protein.

Peter Ottsjö

May 2, 2026

•

3 min read

The TOP10 AI x bio stories in April

Billion-dollar deals, enzymes nature never made, and virtual patients built from 7.2 million real ones.

Peter Ottsjö

Here's the Human Genome Project for virtual cells

Apr 29, 2026

•

6 min read

Here's the Human Genome Project for virtual cells

Plus: Lilly’s $2.25B bet on AI-designed gene insertion, a literature agent that reads the pictures, and the FDA takes aim at the clinical trial bottleneck.

Peter Ottsjö